Title | NF-κB Restricts Inflammasome Activation via Elimination of Damaged Mitochondria. |
Publication Type | Journal Article |
Year of Publication | 2016 |
Authors | Zhong Z, Umemura A, Sanchez-Lopez E, Liang S, Shalapour S, Wong J, He F, Boassa D, Perkins G, Ali SRaza, McGeough MD, Ellisman MH, Seki E, Gustafsson AB, Hoffman HM, Diaz-Meco MT, Moscat J, Karin M |
Journal | Cell |
Volume | 164 |
Issue | 5 |
Pagination | 896-910 |
Date Published | 2016 Feb 25 |
ISSN | 1097-4172 |
Keywords | Adaptor Proteins, Signal Transducing, Animals, Heat-Shock Proteins, Inflammasomes, Interleukin-1beta, Lipopolysaccharides, Macrophages, Mice, Mitochondria, NF-kappa B p50 Subunit, Reactive Oxygen Species, Sequestosome-1 Protein, Ubiquitin-Protein Ligases |
Abstract | Nuclear factor κB (NF-κB), a key activator of inflammation, primes the NLRP3-inflammasome for activation by inducing pro-IL-1β and NLRP3 expression. NF-κB, however, also prevents excessive inflammation and restrains NLRP3-inflammasome activation through a poorly defined mechanism. We now show that NF-κB exerts its anti-inflammatory activity by inducing delayed accumulation of the autophagy receptor p62/SQSTM1. External NLRP3-activating stimuli trigger a form of mitochondrial (mt) damage that is caspase-1- and NLRP3-independent and causes release of direct NLRP3-inflammasome activators, including mtDNA and mtROS. Damaged mitochondria undergo Parkin-dependent ubiquitin conjugation and are specifically recognized by p62, which induces their mitophagic clearance. Macrophage-specific p62 ablation causes pronounced accumulation of damaged mitochondria and excessive IL-1β-dependent inflammation, enhancing macrophage death. Therefore, the "NF-κB-p62-mitophagy" pathway is a macrophage-intrinsic regulatory loop through which NF-κB restrains its own inflammation-promoting activity and orchestrates a self-limiting host response that maintains homeostasis and favors tissue repair. |
DOI | 10.1016/j.cell.2015.12.057 |
Alternate Journal | Cell |
PubMed ID | 26919428 |
PubMed Central ID | PMC4769378 |
Grant List | R01 AI052430 / AI / NIAID NIH HHS / United States R01 CA155120 / CA / NCI NIH HHS / United States R01 CA192642 / CA / NCI NIH HHS / United States R01 HL087023 / HL / NHLBI NIH HHS / United States P41 GM103412 / GM / NIGMS NIH HHS / United States AI043477 / AI / NIAID NIH HHS / United States DK085252 / DK / NIDDK NIH HHS / United States R01 AA020172 / AA / NIAAA NIH HHS / United States P01 DK098108 / DK / NIDDK NIH HHS / United States CA030199 / CA / NCI NIH HHS / United States GM103412 / GM / NIGMS NIH HHS / United States P42 ES010337 / ES / NIEHS NIH HHS / United States R01 CA172025 / CA / NCI NIH HHS / United States CA163798 / CA / NCI NIH HHS / United States P30 CA030199 / CA / NCI NIH HHS / United States R01 DK085252 / DK / NIDDK NIH HHS / United States MFE-135425 / / Canadian Institutes of Health Research / Canada CA172025 / CA / NCI NIH HHS / United States HL087023 / HL / NHLBI NIH HHS / United States AI52430 / AI / NIAID NIH HHS / United States AA020172 / AA / NIAAA NIH HHS / United States CA192642 / CA / NCI NIH HHS / United States ES010337 / ES / NIEHS NIH HHS / United States CA132847 / CA / NCI NIH HHS / United States R01 CA132847 / CA / NCI NIH HHS / United States R01 CA163798 / CA / NCI NIH HHS / United States R01 AI043477 / AI / NIAID NIH HHS / United States |
Related Faculty:
Jorge Moscat, Ph.D. Maria Diaz-Meco Conde, Ph.D.